SG11201903454VA - Immunologically discernible cell surface variants for use in cell therapy - Google Patents
Immunologically discernible cell surface variants for use in cell therapyInfo
- Publication number
- SG11201903454VA SG11201903454VA SG11201903454VA SG11201903454VA SG11201903454VA SG 11201903454V A SG11201903454V A SG 11201903454VA SG 11201903454V A SG11201903454V A SG 11201903454VA SG 11201903454V A SG11201903454V A SG 11201903454VA SG 11201903454V A SG11201903454V A SG 11201903454VA
- Authority
- SG
- Singapore
- Prior art keywords
- isoform
- cell
- international
- basel
- rule
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 8
- 238000002659 cell therapy Methods 0.000 title abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 9
- 102000001708 Protein Isoforms Human genes 0.000 abstract 9
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 108010052285 Membrane Proteins Proteins 0.000 abstract 5
- 102000018697 Membrane Proteins Human genes 0.000 abstract 5
- 108700028369 Alleles Proteins 0.000 abstract 3
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70589—CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16196858 | 2016-11-02 | ||
EP16196860 | 2016-11-02 | ||
PCT/EP2017/059799 WO2017186718A1 (fr) | 2016-04-25 | 2017-04-25 | Édition d'allèles et ses applications |
EP17197820 | 2017-10-23 | ||
PCT/EP2017/077826 WO2018083071A1 (fr) | 2016-11-02 | 2017-10-30 | Variants de surface cellulaire discernables sur le plan immunologique destinés à être utilisés en thérapie cellulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903454VA true SG11201903454VA (en) | 2019-05-30 |
Family
ID=62075802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903454VA SG11201903454VA (en) | 2016-11-02 | 2017-10-30 | Immunologically discernible cell surface variants for use in cell therapy |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190365806A1 (fr) |
EP (2) | EP4360639A3 (fr) |
JP (2) | JP7305539B2 (fr) |
KR (2) | KR20240043810A (fr) |
CN (1) | CN110191948A (fr) |
AU (1) | AU2017355218B2 (fr) |
BR (1) | BR112019008975A2 (fr) |
CA (1) | CA3041582A1 (fr) |
DK (1) | DK3535392T3 (fr) |
FI (1) | FI3535392T3 (fr) |
IL (1) | IL266362B2 (fr) |
LT (1) | LT3535392T (fr) |
MX (1) | MX2019005125A (fr) |
SG (1) | SG11201903454VA (fr) |
WO (1) | WO2018083071A1 (fr) |
ZA (1) | ZA201902426B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
WO2017186718A1 (fr) | 2016-04-25 | 2017-11-02 | Universität Basel | Édition d'allèles et ses applications |
JP7288402B2 (ja) * | 2017-02-17 | 2023-06-07 | パーデュー・リサーチ・ファウンデーション | 細胞医療用の標的リガンド-ペイロードによる薬剤デリバリー |
CN110662554A (zh) | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | 用于抑制谱系特异性蛋白质的组合物和方法 |
CA3082410A1 (fr) * | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Therapies immunocellulaires multifonctionnelles |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
KR20200096769A (ko) | 2017-11-14 | 2020-08-13 | 아르셀엑스, 인크. | D-도메인 함유 폴리펩타이드 및 이의 용도 |
EP3794130A4 (fr) | 2018-05-16 | 2022-07-27 | Synthego Corporation | Méthodes et systèmes de conception et d'utilisation d'arn guide |
AU2019295855A1 (en) * | 2018-06-29 | 2021-01-28 | City Of Hope | CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders |
BR112021003670A2 (pt) | 2018-08-28 | 2021-05-18 | Vor Biopharma, Inc. | células-tronco hematopoéticas geneticamente modificadas e seus usos |
EP3844274A1 (fr) * | 2018-08-28 | 2021-07-07 | Roche Innovation Center Copenhagen A/S | Manipulation de néoantigène à l'aide de composés de modulation d'épissage |
US20230076643A1 (en) * | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
KR102347797B1 (ko) * | 2020-03-03 | 2022-01-07 | 한국과학기술원 | 대식세포 세포 표면 항원 및 이의 다양한 용도 |
WO2021195536A1 (fr) * | 2020-03-27 | 2021-09-30 | The Trustees Of Indiana University | Cibles immunothérapeutiques dans le myélome multiple et procédés pour leur identification |
WO2022150831A1 (fr) * | 2021-01-07 | 2022-07-14 | Innovative Cellular Therapeutics Holdings, Ltd. | Cellules car et molécules de liaison polyspécifiques pour le traitement d'une tumeur solide |
CN112852875B (zh) * | 2021-02-26 | 2022-10-21 | 福建省立医院 | 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法 |
CN113125718A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的45抗体试剂盒及应用 |
CN113125754A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的23抗体试剂盒及应用 |
CN113125733A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的42抗体试剂盒及应用 |
CN113109575A (zh) * | 2021-04-16 | 2021-07-13 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的40抗体试剂盒及应用 |
CN113125755A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的9抗体试剂盒及应用 |
CN114391102A (zh) * | 2021-05-27 | 2022-04-22 | 中科蓝华(广州)生物医药技术有限公司 | 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒 |
WO2023283585A2 (fr) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Oligonucléotides d'inhibition et méthodes d'utilisation de ceux-ci |
CA3228272A1 (fr) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions et procedes de modification genetique |
EP4380693A1 (fr) | 2021-08-06 | 2024-06-12 | Universität Basel | Variants de protéine de surface cellulaire discernables destinés à être utilisés en thérapie cellulaire |
WO2023111311A1 (fr) | 2021-12-16 | 2023-06-22 | Universität Basel | Variants de protéine de surface cellulaire discernable de cd117 destinés à être utilisés en thérapie cellulaire |
CA3240875A1 (fr) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Variants de proteine de surface cellulaire discernable de cd45 destines a etre utilises en therapie cellulaire |
CN114292830B (zh) * | 2021-12-31 | 2024-05-03 | 复旦大学 | 蛋白SaCas9的抗原表位及其在基因编辑中的应用 |
WO2024015925A2 (fr) * | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions et méthodes de génération de motif de reconnaissance du proto-espaceur (pam) artificiel |
WO2024073751A1 (fr) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Procédés et compositions pour la modification et l'enrichissement de gènes |
WO2024097131A1 (fr) * | 2022-11-04 | 2024-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Rééquilibrage du système immunitaire par déplétion de cellules souches hématopoïétiques orientées production de myéloïdes |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002070738A2 (fr) * | 2001-03-07 | 2002-09-12 | Andre Schuh | Diagnostic et traitement des troubles sanguins |
EP1674479A1 (fr) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation des récepteurs Fc gamma pour optimiser l'immunothérapie |
ES2642205T3 (es) * | 2006-11-03 | 2017-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto |
US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
JP5688734B2 (ja) * | 2008-12-12 | 2015-03-25 | 国立大学法人 東京大学 | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 |
JP6620018B2 (ja) | 2012-12-06 | 2019-12-11 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC | Crisprに基づくゲノム修飾および制御 |
WO2014164680A1 (fr) * | 2013-03-12 | 2014-10-09 | Molecular Templates, Inc. | Immunotoxines de liaison à cd20 pour induire une internalisation cellulaire et procédés les utilisant |
AU2014274916B2 (en) | 2013-06-05 | 2019-10-31 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
CA2914213A1 (fr) * | 2013-06-17 | 2014-12-24 | Alain Moreau | Methode d'augmentation de signalisation de gipcr dans les cellules d'un sujet scoliotique |
US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
EP3025719B1 (fr) * | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combinaison d'immunothérapie de récepteurs reconnaissant un antigène et cellules hématopoïétiques pour le traitement de maladies |
SG10202107602XA (en) * | 2015-11-04 | 2021-08-30 | Univ Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
EP3416976A2 (fr) * | 2016-02-16 | 2018-12-26 | Yale University | Compositions permettant d'améliorer l'édition ciblée de gènes et leurs procédés d'utilisation |
EP3430142A1 (fr) * | 2016-03-14 | 2019-01-23 | Editas Medicine, Inc. | Méthodes et compositions liées à crispr/cas pour traiter les bêta-hémoglobinpathies |
WO2017186718A1 (fr) * | 2016-04-25 | 2017-11-02 | Universität Basel | Édition d'allèles et ses applications |
-
2017
- 2017-10-30 KR KR1020247009264A patent/KR20240043810A/ko unknown
- 2017-10-30 LT LTEPPCT/EP2017/077826T patent/LT3535392T/lt unknown
- 2017-10-30 CA CA3041582A patent/CA3041582A1/fr active Pending
- 2017-10-30 MX MX2019005125A patent/MX2019005125A/es unknown
- 2017-10-30 JP JP2019521099A patent/JP7305539B2/ja active Active
- 2017-10-30 KR KR1020197015826A patent/KR20190072639A/ko not_active IP Right Cessation
- 2017-10-30 US US16/346,185 patent/US20190365806A1/en active Pending
- 2017-10-30 FI FIEP17797585.1T patent/FI3535392T3/fi active
- 2017-10-30 DK DK17797585.1T patent/DK3535392T3/da active
- 2017-10-30 EP EP24155910.3A patent/EP4360639A3/fr active Pending
- 2017-10-30 EP EP17797585.1A patent/EP3535392B1/fr active Active
- 2017-10-30 SG SG11201903454VA patent/SG11201903454VA/en unknown
- 2017-10-30 AU AU2017355218A patent/AU2017355218B2/en active Active
- 2017-10-30 BR BR112019008975A patent/BR112019008975A2/pt unknown
- 2017-10-30 CN CN201780067985.1A patent/CN110191948A/zh active Pending
- 2017-10-30 WO PCT/EP2017/077826 patent/WO2018083071A1/fr active Application Filing
-
2019
- 2019-04-16 ZA ZA2019/02426A patent/ZA201902426B/en unknown
- 2019-04-30 IL IL266362A patent/IL266362B2/en unknown
-
2023
- 2023-06-28 JP JP2023105962A patent/JP2023126852A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
LT3535392T (lt) | 2024-04-25 |
WO2018083071A1 (fr) | 2018-05-11 |
US20190365806A1 (en) | 2019-12-05 |
EP4360639A3 (fr) | 2024-07-17 |
JP2023126852A (ja) | 2023-09-12 |
EP3535392A1 (fr) | 2019-09-11 |
BR112019008975A2 (pt) | 2019-07-09 |
EP3535392B1 (fr) | 2024-03-27 |
RU2019116783A3 (fr) | 2021-03-05 |
MX2019005125A (es) | 2019-08-29 |
AU2017355218B2 (en) | 2024-02-22 |
KR20240043810A (ko) | 2024-04-03 |
FI3535392T3 (fi) | 2024-05-23 |
IL266362B1 (en) | 2024-03-01 |
RU2019116783A (ru) | 2020-12-03 |
CN110191948A (zh) | 2019-08-30 |
JP7305539B2 (ja) | 2023-07-10 |
KR20190072639A (ko) | 2019-06-25 |
ZA201902426B (en) | 2020-10-28 |
IL266362A (en) | 2019-06-30 |
DK3535392T3 (da) | 2024-04-22 |
AU2017355218A1 (en) | 2019-05-02 |
JP2019533450A (ja) | 2019-11-21 |
CA3041582A1 (fr) | 2018-05-11 |
IL266362B2 (en) | 2024-07-01 |
EP4360639A2 (fr) | 2024-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
SG11201903282TA (en) | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | |
SG11201809522WA (en) | Method of nucleic acid sequence determination | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
SG11201801401UA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
SG11201908980PA (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
SG11201805941WA (en) | Tgfbeta 2 antibodies |